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INTRODUCTION
It is well known that good metabolic control can delay or
prevent diabetes related complications (1-3). In general, basic
patient management programs involving diet, exercise, proper
patient education, and medication are important for achiev-
ing good metabolic control in diabetes mellitus patients. In
addition to these basic programs, the frequent and regular
monitoring of blood glucose profiles is crucial in terms of
predicting outcome and planning treatment strategies (4).
However, a single glucose profile obtained during a visit to
a clinic provides only superficial information and glucose
level testing during a clinic visit is less attractive than daily
glucose level checking by patients themselves. For this rea-
son, glucose self-monitoring is important in patients with
diabetes mellitus.
Currently self glucose monitoring is mainly performed by
obtaining a small amount of blood by finger pricking. How-
ever, this method entails apprehension and pain, which results
in alarmingly low compliance. According to a study by NH-
ANES, only 47% of diabetes patients with a HbA1c  level
>8% and 32% of diabetes patients with a HbA1c level <8%
check their glucose level more than once a day (5). In Korea,
according to the Diabcare study conducted in 2001, only
17% of diabetes patients managed at private clinics check
their glucose level on a regular basis (6). These findings all
too clearly indicate that a considerable proportion of diabetes
patients are receiving inadequate management.
However, even the conventionally recommended frequen-
cy of glucose level checking of 4 times a day is rather limited
in terms of conveying information on plasma glucose level
changes. Some diabetes centers utilize more progressive me-
thods of glucose monitoring, such as, the Continuous glucose
monitoring system (CGMSTM, Medtronic MiniMed compa-
ny, Northridge, CA, U.S.A.) to detect daily changes in the
interstitial fluid glucose levels, but this system also has the
fundamental limitation that it cannot be easily operated by
a patient.
Recently, a non-invasive continuous method of measuring
glucose concentration in interstitial fluid was introduced,
based on the principle of reverse iontophoresis. The Gluco-
WatchTM‚ automatic glucose biographer (Cygnus, Inc., Red-
wood, CA, U.S.A.) is the first commercially useful device
based on this technology, and many clinical studies conduct-
ed to investigate its practical uses have returned favorable
results.
Sang Youl Rhee*
,� , Suk Chon*
,� , 
Gwanpyo Koh*
,� , Jeong Ryung Paeng
� ,
Seungjoon Oh*
,� , Jeong-taek Woo*
,� ,
Sung Woon Kim*
,� , Jin-Woo Kim*
,� ,
Young Seol Kim*
,�
Departments of Endocrinology and Metabolism*,
Research Institute of Endocrinology
� , College of
Medicine, Kyung Hee University, Seoul, Korea
Address for correspondence
Young Seol Kim, M.D.
Departments of Endocrinology and Metabolism, College
of Medicine, Kyung Hee University, 1 Hoiki-dong,
Dongdaemoon-gu, Seoul 130-701, Korea 
Tel : +82.2-958-8199, Fax : +82.2-968-1848
E-mail : kimys@khmc.or.kr
*This work was supported from the Korean National
Diabetes Program of the Korean Ministry of Health and
Welfare (Grant No. A050463).
70
J Korean Med Sci 2007; 22: 70-3
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Clinical Experience of an Iontophoresis Based Glucose Measuring
System
Currently finger pricking is the common method of blood glucose measurement in
patients with diabetes mellitus. However, diabetes patients have proven to be reluc-
tant to check their glucose profiles regularly because of the discomfort associated
with this technique. Recently, a non-invasive and continuous Reverse Iontophore-
sis based Glucose Monitoring Device (RIGMD) was developed in Korea. The study
was conducted during the period November 2003-January 2004 on 19 in-patients.
Glucose measurements were performed using RIGMD between 10 a.m. and 4 p.m.
Concurrent plasma glucose levels were checked hourly and subsequently compared
with RIGMD data. The mean error of RIGMD measurements was -3.45± ±52.99 mg/
dL with a mean absolute relative error of 20± ±15.16%. Measurements obtained by
RIGMD were correlated with plasma glucose levels (correlation coefficient; 0.784
(p<0.05)) and this correlation was independent of time of data collection. However,
after excluding confounding variables this correlation coefficient exhibited a tenden-
cy to increase. 98.9% of the results were clinically acceptable by Clarke error grid
analysis. We concluded that RIGMD does not have the reliability and accuracy re-
quired to wholly replace conventional methods. However, further technical advance-
ments that reduce its shortcomings would make this device useful for the manage-
ment of diabetes.
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A non-invasive glucose monitoring device based on the
same principle has also been developed in Korea. This device
is tentatively called Reverse Iontophoresis based Glucose Moni-
toring Device (RIGMD), and it detects and measures inter-
stitial fluid glucose concentrations via an electrochemical en-
zymatic sensor every 5 min. In this study, the authors inves-
tigated the accuracy and clinical acceptability of this new
device by comparing the data obtained from it and plasma
glucose levels obtained by venous sampling.
MATERIALS AND METHODS
Operating principle of RIGMD
The operating principle of RIGMD was first described in
studies that described experiments conducted in vivo in 1995
(7, 8), and is essentially the same as that utilized by the Glu-
coWatchTM‚ automatic glucose biographer. Briefly, these de-
vices measure fine electrical currents that dependent on glu-
cose concentrations in interstitial fluid by using an electro-
chemical enzymatic sensor located on forearm skin. The sen-
sor is composed of electrodes and a gelatinous material which
contains glucose oxidase (GOx). A microcurrent is produced
between the electrodes, which causes reverse iontophoresis
that extracts glucose from skin interstitial fluid. The extract-
ed glucose is then converted into gluconic acid and H2O2 by
the glucose oxidase contained in sensor gel.
Glucose+O2 GOx → gluconic acid+H2O2
Current is produced by reducing H2O2 to O2 by electrocat-
alytic oxidation and current differences represent the chang-
ing glucose concentrations in interstitial fluid.
H2O2 → O2+2H
++2e
-
Study subjects
Initial candidates for this study were selected from among
type 1 and type 2 diabetes mellitus patients admitted to the
Department of Endocrinology and Metabolism in Kyung Hee
University Hospital between November 2003 and January
2004. Nine of the 28 candidates were subsequently exclud-
ed due to voluntary or non-voluntary discontinuation of the
device or noncompliance, leaving a total of 19 study subjects.
The exclusion criteria were: 1) continuous hypo- or hyper-
glycemia (<40 mg/dL or >450 mg/dL); 2) electronic auxil-
iaries fitted such as cardiac pace maker; 3) an abruption or
injury to forearm skin; 4) acetaminophen administration with-
in 72 hr of the initiation of the data-collection; 5) mentally
illness; 6) peripheral vascular disease; or 7) anemia.
Study protocol
To evaluate the accuracy and reliability of RIGMD, glucose
levels were simultaneously checked hourly in each patient
from 10 a.m. to 4 p.m. using RIGMD and by antecubital
venous blood sampling; plasma glucose levels were measured
using a Biosen analyzer (Biosen 5030; EKF-diagnostic GmbH,
Magdeburg, Germany). The first set of data taken at 10 a.m.
was used to calibrate the RIGMD vs. plasma glucose levels
as determined by vs. sampling. Unwanted side effects at sen-
sor/skin contact site were also noted.
Data analysis
All statistical manipulations were performed using SPSS
Version 11.0 (SPSS Inc., Chicago, IL, U.S.A.). Correlation
coefficients, slopes and intercepts were calculated using lin-
ear regression analysis. Mean absolute relative error (MARE),
mean error (ME), and other comparative descriptive statisti-
cal values were also calculated for the RIGMD and plasma
glucose level testing. The Clarke error grid was utilized to
evaluate the clinical applicability of RIGMD.
RESULTS
Patients demographics
Nineteen patients successfully completed the study. There
were 9 males and 10 females of mean age 53.52±15.56 yr.
Mean disease duration was 7.11±5.70 yr with a mean HbA1c
level of 8.36±2.5%.
Mean error and Mean absolute relative error
Excluding the 10 a.m. data set, which was used for calibra-
tion, all other measurements were subjected to statistical anal-
ysis. Differences between measurements are described as ME,
and ME divided by the plasma glucose level was defined as
the MARE. The mean difference between the paired data
was -3.45±52.99 mg/dL with a MARE of 20±15.16%
(Table 1).
Minimum Maximum Mean SD
Plasma glucose 75 378 216.147 68.173
RIGMD 51 395 212.695 73.790
ME (mg/dL) -139 136 -3.4526 52.99554
MARE (%) 0.00 264.24 20.4150 15.16707
Table 1. Mean error (ME) and mean absolute relative error (MA-
RE) of plasma glucose levels and interstitial glucose levels by
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Linear regression analysis
Data from RIGMD was found to be statistically correlated
with plasma glucose level by linear regression analysis (r2=
0.524; correlation coefficient 0.784, p<0.05) (Fig. 1). Corre-
lation coefficients for hourly measurements were also calcu-
lated to determine whether or not time elapsed or a reduction
in battery power affected determined glucose oxidase activi-
ties. These correlation coefficients were also high, most were
within 0.65-0.7, and they remained near constant through-
out the study. However, the correlation coefficient between
of data taken at 120 min from the start was found to be con-
siderably lower. Adjusted correlation coefficients, i.e., after
correcting for confounding factors, such as age and gender,
were generally higher; however correlation coefficient of data
taken 120 min from start remained low even after correction
(Table 2).
Clarke error grid analysis
Clarke examined the clinical validity of a glucose monitor-
ing system using an error grid (9). According to this error
grid system, the measurements from RIGMD and plasma
glucose levels are represented as a scatter plot, which is then
divided into 5 zones. Data set falling within zones A and B
are defined as clinically acceptable, and data falling within
the other zones (C, D, and E) as clinically unacceptable (Table
3). In the present study, only a single set of data fell outside
the acceptable zone (into zone C), leaving 98.9% of the data
sets within zones A and B, indicating that RIGMD is clini-
cally acceptable (Fig. 2).
Side effects
Transient itching or erythema was observed at the sensor
attachment area in 10.5% (2 of 19) of the subjects. This was
thought to be due to the sensor current, and subsided with-
in 90 min after sensor detachment. No specific device com-
plication was discovered during subsequent outpatient fol-
low-up.
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Fig. 1. Linear regression analysis result, showing the relationship
between plasma glucose level and interstitial glucose level as
determined by RIGMD.
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Fig. 2. Clarke error grid analysis of plasma glucose level and in-
terstitial glucose level by RIGMD results.
Zone Description Meaning
Number
(Total 95)
A Clinically accurate, would  Clinically acceptable 49
lead to correct treatment  (51.6%)
decisions
B Would lead to benign  45
decisions or no treatment (47.4%)
C Would lead to overcorrection  Clinically 1
of normal glucose levels significant errors (1.1%)
D Would lead to failure to  0
detect and treat high or  (0%)
low glucose levels
E Would lead to erroneous 0
treatment decisions (0%)
Table 3. Definition of Clarke error grid zones and the number of
pairs included in each zone
*p<0.01 (by Spearman’s rho); 
� Partial correlation coefficient adjusted to
age, sex, duration of diseases, other comorbidity, and patient body mass
index and HbA1c.
60 min 120 min 180 min 240 min 300 min
Correlation coefficient 0.735* 0.673* 0.729* 0.656* 0.793*
Adjusted correlation  0.857
� 0.456
� 0.772
� 0.666
� 0.852
�
coefficient
Table 2. Correlation coefficients and adjusted correlation coef-
ficients between plasma glucose level and interstitial glucose
level by RIGMDIontophoresis Based Glucose Measuring System 73
DISCUSSION
Several studies have been performed on non-invasive and
continuous glucose level monitoring using reverse iontophore-
sis in vivo (Rao et al. [7, 10] and Tamada et al. [8]). Cygnus
Inc. (U.S.A.) is currently marketing a device based on this
technology called GlucoWatchTM biographer.
Garg et al. (11) calculated correlation coefficients between
finger prick blood glucose levels and GlucoWatchTM deter-
mined levels in 28 type 1 diabetes mellitus patients, and ob-
tained correlation coefficient in the r=0.85-0.90 range, and
96% of the measurements were clinically acceptable based
on the Clarke error grid analysis. In addition, Tamada et al.
(12) performed a study on 92 type 1 and 2 diabetes mellitus
patients and also obtained a high correlation coefficient of
r=0.88, and found that 96.8% of measurements were clini-
cally acceptable based on the error grid analysis.
The correlation coefficient of the present study (r=0.784)
was lower than those of prior GlucoWatchTM‚ biographer stud-
ies. Notably, the correlation coefficient calculated from mea-
surements taken at 120 min after start up was markedly lower
than those calculated at other times. In addition, the present
study was conducted on fewer subjects than the aforemention-
ed studies, which would have resulted in lower reliability.
Although the relatively large measurement error could be
attributed to a lack of reliability of RIGMD vs. GlucoWatchTM
biographer. It should be noted that in previous studies on
GlucoWatchTM biographer, blood glucose levels were deter-
mined using the finger prick method and not by using plas-
ma glucose levels measured directly from blood drawn from
the forearm, as in the present study. Glucose levels in drawn
blood probably better reflect patient glucose profile. This
point warrants consideration when tests on GlucoWatchTM
biographer are next performed.
Acetaminophen is known to potentially interfere with con-
ventional glucose monitoring devices. For this reason, sub-
jects taking acetaminophen were excluded from the present
study. However, according to a study conducted by Tierney
et al. (13), subjects being administered acetaminophen daily
at 1,000 mg had glucose levels as measured by GlucoWatchTM
biographer and by finger prick method that differed by <20%
and had clinically acceptable error grid analysis results. Since
RIGMD incorporates the same basic principle as Gluco-
WatchTM biographer a guess can not be effected to acetamino-
phen administration. However, further clinical studies are
required to confirm this relation.
Currently, some limitations restrict the clinical application
of RIGMD. For example, the accuracy of RIGMD needs to
be investigated to account for the following possible effects,
i.e., low or high temperature, in the presence of excessive per-
spiration at the sensor site, the effects of site location, skin
thickeness, etc. Thus, to popularize such methods among
diabetes patients, more clinical study of RIGMD is required
to provide medical staff and patients with more comprehen-
sive data on daily plasma glucose level shifts and ultimately
lead to better management.
The present study shows that as yet RIGMD is not suffici-
ently reliable or accurate enough to replace conventional me-
thods of monitoring glucose. However, if the device could be
made more accurate and convenient we believe that it would
offer a highly effective means of glucose level self-testing. 
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